↓ Skip to main content

Dove Medical Press

Article Metrics

Role of pirfenidone in the management of pulmonary fibrosis

Overview of attention for article published in Therapeutics and Clinical Risk Management, April 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#29 of 1,100)
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
2 news outlets
twitter
6 tweeters
facebook
2 Facebook pages
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
70 Mendeley
Title
Role of pirfenidone in the management of pulmonary fibrosis
Published in
Therapeutics and Clinical Risk Management, April 2017
DOI 10.2147/tcrm.s81141
Pubmed ID
Authors

Keith Meyer, Catherine Decker

Abstract

Pulmonary fibrosis is associated with a number of specific forms of interstitial lung disease (ILD) and can lead to progressive decline in lung function, poor quality of life, and, ultimately, early death. Idiopathic pulmonary fibrosis (IPF), the most common fibrotic ILD, affects up to 1 in 200 elderly individuals and has a median survival that ranges from 3 to 5 years following initial diagnosis. IPF has not been shown to respond to immunomodulatory therapies, but recent trials with novel antifibrotic agents have demonstrated lessening of lung function decline over time. Pirfenidone has been shown to significantly slow decline in forced vital capacity (FVC) over time and prolong progression-free survival, which led to its licensing by the United States Food and Drug Administration (FDA) in 2014 for the treatment of patients with IPF. However, pirfenidone has been associated with significant side effects, and patients treated with pirfenidone must be carefully monitored. We review recent and ongoing clinical research and experience with pirfenidone as a pharmacologic therapy for patients with IPF, provide a suggested approach to incorporate pirfenidone into a treatment algorithm for patients with IPF, and examine the potential of pirfenidone as a treatment for non-IPF forms of ILD accompanied by progressive pulmonary fibrosis.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 70 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 17%
Researcher 8 11%
Other 6 9%
Student > Postgraduate 6 9%
Student > Master 5 7%
Other 11 16%
Unknown 22 31%
Readers by discipline Count As %
Medicine and Dentistry 20 29%
Pharmacology, Toxicology and Pharmaceutical Science 6 9%
Nursing and Health Professions 6 9%
Biochemistry, Genetics and Molecular Biology 4 6%
Agricultural and Biological Sciences 4 6%
Other 8 11%
Unknown 22 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2020.
All research outputs
#851,045
of 17,364,317 outputs
Outputs from Therapeutics and Clinical Risk Management
#29
of 1,100 outputs
Outputs of similar age
#22,779
of 272,926 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 19 outputs
Altmetric has tracked 17,364,317 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,100 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,926 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.